Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant WX-0593 in Resectable ALK/ROS1+ NSCLC
NCT05765877Phase 2Recruiting
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iruplinalkib in non-small cell lung cancer (NSCLC). Started Mar 2023; status: recruiting.
02
Drugs
iruplinalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05765877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765877.